JP2014517832A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517832A5
JP2014517832A5 JP2014509736A JP2014509736A JP2014517832A5 JP 2014517832 A5 JP2014517832 A5 JP 2014517832A5 JP 2014509736 A JP2014509736 A JP 2014509736A JP 2014509736 A JP2014509736 A JP 2014509736A JP 2014517832 A5 JP2014517832 A5 JP 2014517832A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
composition according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014509736A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/058678 external-priority patent/WO2012152882A1/en
Publication of JP2014517832A publication Critical patent/JP2014517832A/ja
Publication of JP2014517832A5 publication Critical patent/JP2014517832A5/ja
Pending legal-status Critical Current

Links

JP2014509736A 2011-05-10 2012-05-10 自己免疫疾患を治療するための方法及び医薬組成物 Pending JP2014517832A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305557.8 2011-05-10
EP11305557 2011-05-10
PCT/EP2012/058678 WO2012152882A1 (en) 2011-05-10 2012-05-10 Methods and pharmaceutical compositions for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2014517832A JP2014517832A (ja) 2014-07-24
JP2014517832A5 true JP2014517832A5 (US20090208454A1-20090820-C00047.png) 2015-05-28

Family

ID=44653630

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509736A Pending JP2014517832A (ja) 2011-05-10 2012-05-10 自己免疫疾患を治療するための方法及び医薬組成物

Country Status (5)

Country Link
US (1) US20140086895A1 (US20090208454A1-20090820-C00047.png)
EP (1) EP2707018B1 (US20090208454A1-20090820-C00047.png)
JP (1) JP2014517832A (US20090208454A1-20090820-C00047.png)
ES (1) ES2560012T3 (US20090208454A1-20090820-C00047.png)
WO (1) WO2012152882A1 (US20090208454A1-20090820-C00047.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment
CA2936694A1 (en) * 2014-01-13 2015-07-16 Berg Llc Enolase 1 (eno1) compositions and uses thereof
US20160375113A1 (en) * 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
AU2021356099A1 (en) * 2020-10-06 2023-05-25 European Molecular Biology Laboratory Screening method for the identification of novel therapeutic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929758A (en) 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4102877A (en) 1976-07-28 1978-07-25 Merck & Co., Inc. Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US20100047256A1 (en) * 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
WO2010117694A2 (en) * 2009-03-30 2010-10-14 Prometheus Laboratories Inc. Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
US20150218546A1 (en) * 2011-04-05 2015-08-06 Lars Klareskog Novel peptides that bind to types of mhc class ii and their use on diagnosis and treatment

Similar Documents

Publication Publication Date Title
JP2017048194A5 (US20090208454A1-20090820-C00047.png)
JP2014501510A5 (US20090208454A1-20090820-C00047.png)
HRP20170468T1 (hr) Bispecifična protutijela protiv baff i protiv il-17
JP2015514395A5 (US20090208454A1-20090820-C00047.png)
JP2012126742A5 (US20090208454A1-20090820-C00047.png)
RU2016146198A (ru) Терапевтические dll4-связывающие белки
JP2013523179A5 (US20090208454A1-20090820-C00047.png)
JP2010166916A5 (US20090208454A1-20090820-C00047.png)
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
GB201206559D0 (en) Polypeptide
JP2015533791A5 (US20090208454A1-20090820-C00047.png)
JP2012115277A5 (US20090208454A1-20090820-C00047.png)
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
JP2011177189A5 (US20090208454A1-20090820-C00047.png)
JP2013048638A5 (US20090208454A1-20090820-C00047.png)
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
HRP20210734T1 (hr) Koštani morfogenetski proteini
WO2013000922A9 (en) Ccr2 antagonist peptides
WO2011036445A3 (en) Polypeptides and uses thereof
JP2013539454A5 (US20090208454A1-20090820-C00047.png)
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
JP2014517832A5 (US20090208454A1-20090820-C00047.png)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
WO2012123959A3 (en) Copolymer-1, process for preparation and analytical methods thereof
JP2014529399A5 (US20090208454A1-20090820-C00047.png)